Prestige Consumer Healthcare's Stock Plummets Amid Investigation of Supply Chain Issues

Prestige Consumer Healthcare's Stock Challenges Amid Investigation

In a surprising turn of events, Prestige Consumer Healthcare Inc. (NYSE: PBH) experienced a sharp decline in its stock price, plummeting over 11% on May 14, 2026. This significant drop followed the company’s dismal announcement about revenue declines and operational setbacks affecting its flagship products.

The decrease in share price has prompted the national law firm Hagens Berman to conduct an investigation into whether Prestige adequately informed investors about its supply chain issues and its ability to effectively address them prior to the critical date. The firm is particularly concerned about whether Prestige potentially violated federal securities laws by lacking transparency regarding their operational challenges.

Prestige is widely recognized for its development and sale of over-the-counter (OTC) health and personal care products, with Clear Eyes®, a popular line of eye drops, being one of the brand’s most notable offerings. These eye drops are known for providing relief from symptoms like redness, dryness, and itchiness. However, in its latest earnings call, company officials revealed significant supply chain constraints associated with Clear Eyes® that directly impacted its Q4 2026 financial performance.

On May 13, 2026, Prestige reported revenues for Q4 that were 5% lower than the same quarter the previous year and 6.4% lower than the preceding quarter. Of particular concern was the revelation that revenues from the North America OTC Eye and Ear Care market - where Clear Eyes® is categorized - fell dramatically by 20.6% year-over-year, while international revenues plummeted by 31.3%. These figures indicate a troubling downward trend for the company in a fiercely competitive market.

Further complicating matters, during the earnings call, management disclosed ongoing operational problems at its recently acquired Pillar5 facility, which had previously been touted as a solution to Clear Eyes® supply constraints. Company officials admitted that what was anticipated to be a short shutdown for maintenance at Pillar5 unexpectedly extended, leading to prolonged disruptions in production.

Reed Kathrein, a partner at Hagens Berman overseeing the investigation, stated, “Our focus is on determining when Prestige and its management were first aware of the Pillar5 facility’s underperformance and whether they misled investors about the progress in resolving Clear Eyes® supply challenges.”

This ongoing investigation is not merely an academic exercise; individuals who have invested in Prestige and incurred substantial losses may be encouraged to come forward. Hagens Berman’s outreach aims to gather information from investors that could support the firm’s claims moving forward.

Whistleblowers with non-public information about Prestige’s operations also have avenues to assist in the investigation via the SEC Whistleblower program, potentially earning rewards based on the outcome of the enforcement action.

As Prestige navigates through these dire financial challenges, investors are left wondering about the future of the company and its critical brands. Immediate steps will need to be taken to restore stakeholder confidence and reverse the negative momentum surrounding the stock. The developments in this case will undoubtedly attract keen attention from investors and market analysts, as the fallout from these supply chain issues could have far-reaching implications for the company’s market position.

For more updates on this situation, investors can follow Hagens Berman’s announcements and insights. The firm continues to advocate for the rights of investors in holding corporations accountable for their financial disclosures and operational integrity.